LENSAR, Inc.

NASDAQ:LNSR

Medical - Devices

Healthcare
$4.85 -8.15%

-$0.51 today

Market cap
$59.63M
Beta
0.87
P/E (TTM)
2.4
EPS (TTM)
$2.42
52W Low $5.06High $13.47

Volume 0.06M

Average 0.09M

LNSR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

LENSAR, Inc.NASDAQ: LNSR

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of $1.39M fell 9.7% year over year, behind the +1.0% change in trailing-twelve-month research & development. Sequentially, it rose 6.9% from the prior quarter. Over 3 fiscal years it compounded at -21.9% a year.

Context

  • Research & development amounted to 9.6% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -9.7% toward the trailing-twelve-month pace of +1.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.39M+6.9% QoQ
Last fiscal yearDec 2025
$5.62M+5.5% YoY
LTMMar 2026
$5.47M+1.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.7%——
1 year+5.5%——
3-year CAGR-21.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
5.62M USD
Year-over-year change
+5.5%
4-year CAGR
-17.9%

Research & Development vs competitors

How LNSR compares with its peers on the latest reported figures

  • LNSR's LTM Mar 2026 research & development of $5.47M is the lowest of the 10 companies compared; the peer median is $21.15M.
  • Its year-over-year change of +1.0% is the 5th highest of 10, against a peer median of -1.0%.
  • Research & development amounts to 9.5% of revenue for LNSR, versus a peer median of 48.5%.
LNSR Competitors Peer median
Research & Development for LNSR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$74.27M +76.4%+63.2%—
AVRAnteris Technologies Global Corp.LTM Mar 2026$70.12M +24.4%+57.8%3788.3%
CRDFCardiff Oncology, Inc.LTM Mar 2026$31.62M -19.6%+9.2%6022.3%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$26.42M +16.3%+12.0%22.7%
PROFProfound Medical Corp.LTM Mar 2026$21.15M -1.0%+12.6%112.1%
MXCTMaxCyte, Inc.LTM Mar 2026$18.78M -12.5%+2.2%58.2%
OWLTOwlet, Inc.LTM Mar 2026$15.13M +46.7%-20.4%14.1%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$14.89M -1.7%-11.2%33.2%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$13.34M -7.2%+1.9%38.8%
LNSRLENSAR, Inc.LTM Mar 2026$5.47M +1.0%-21.9%9.5%
Peer median (excluding LNSR) $21.15M-1.0%+9.2%48.5%

Competitors are the stored peer set for LNSR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.46M35.36M42.16M53.49M58.44M
Cost of Revenue16.63M15.4M21.06M27.64M31.31M
Gross Profit17.83M19.96M21.11M25.85M27.12M
Gross Margin51.8%56.4%50.1%48.3%46.4%
Research & Development12.36M11.81M6.14M5.33M5.62M
Selling, General & Admin23.89M27.17M26.1M26.49M45.16M
Operating Expenses37.49M40.13M33.34M36.52M51.7M
Depreciation & Amortization2.76M3.41M3.52M3.93M4.5M
EBITDA(16.84M)(16.51M)(10.87M)(3.01M)(29.78M)
EBITDA Margin-48.9%-46.7%-25.8%-5.6%-51.0%
Operating Income(19.65M)(20.18M)(12.23M)(10.67M)(24.58M)
Operating Margin-57.0%-57.1%-29.0%-19.9%-42.1%
Interest Income34K17K85K103K91K
Interest Expense00000
Other Income / Expenses51K263K(2.15M)(20.74M)(9.7M)
Income Before Tax(19.6M)(19.91M)(14.38M)(31.4M)(34.28M)
Pre-Tax Margin-56.9%-56.3%-34.1%-58.7%-58.7%
Income Tax Expense00000
Net Income(19.6M)(19.91M)(14.38M)(31.4M)(34.28M)
Net Margin-56.9%-56.3%-34.1%-58.7%-58.7%
EPS (Basic)(2.10)(1.96)(1.31)(2.73)(2.87)
EPS (Diluted)(2.10)(1.96)(1.31)(2.73)(2.87)
Weighted Avg Shares9.37M10.16M10.97M11.52M11.96M
Weighted Avg Shares (Diluted)9.37M10.16M10.97M11.52M11.96M

LENSAR, Inc.

NASDAQ:LNSR

Intrinsic Alpha fair value

Locked

Current Price

$4.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.